Bailard’s Avanos Medical AVNS Stock Holding History

Bailard’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-16,013	Closed	-$324K	–	714
2023 Q3	$324K	Buy	16,013 +2,251	+16%	+$51K	0.01%	513
2023 Q2	$352K	Buy	+13,762	New	+$362K	0.01%	467

Other funds holding AVNS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bailard's AVNS Position: Q4 2023 in Review

Bailard sold out of Avanos Medical (AVNS) in Q4 2023, closing a stake of 16,013 shares — an estimated $324K sold.

Bailard first reported a position in AVNS in Q2 2023 and held it in 2 quarters. The position peaked at $352K in Q2 2023. 265 funds tracked by Wall St. Rank hold AVNS as of Q4 2023.

Bailard reported no remaining Avanos Medical position as of Q4 2023 after selling out during the quarter.
Bailard sold 16,013 Avanos Medical shares in Q4 2023, an estimated $324K.
Bailard first reported a position in Avanos Medical in Q2 2023 and held it in 2 quarters.
Bailard's Avanos Medical position peaked at $352K in Q2 2023.
265 funds tracked by Wall St. Rank held Avanos Medical as of Q4 2023.

Based on Bailard's 13F filing for Q4 2023, filed 2 Feb 2024.